Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | SLC16A1 | P53985 | 5/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.60 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.60 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087282 | 1.00 | MEN1 (0.73) | MEN1KMT2AGAAPTGDR2ALDH1A1 | |
| SCHEMBL2088057 | 0.90 | MEN1 (0.78) | MEN1KMT2AGAAPTGDR2ALDH1A1 | |
| SCHEMBL2088058 | 0.90 | MEN1 (0.78) | MEN1KMT2AGAAPTGDR2ALDH1A1 | |
| SCHEMBL2087572 | 0.88 | MEN1 (0.75) | MEN1KMT2AGAAPTGDR2ALDH1A1 | |
| SCHEMBL2087570 | 0.88 | MEN1 (0.75) | MEN1KMT2AGAAPTGDR2ALDH1A1 | |
| SCHEMBL2088652 | 0.87 | MEN1 (0.83) | MEN1KMT2AGAAPTGDR2ALDH1A1 | |
| SCHEMBL2088653 | 0.87 | MEN1 (0.83) | MEN1KMT2AGAAPTGDR2ALDH1A1 | |
| SCHEMBL2086476 | 0.86 | MEN1 (0.65) | MEN1KMT2AGAAPTGDR2ALDH1A1 | |
| SCHEMBL2086478 | 0.86 | MEN1 (0.65) | MEN1KMT2AGAAPTGDR2ALDH1A1 | |
| SCHEMBL2087549 | 0.86 | MEN1 (0.82) | MEN1KMT2AGAAPTGDR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | claimed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | claimed |
| EP-1740171-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2007-01-10 | — | — | EP | claimed |
| WO-2005094816-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | claimed |
| US-7897788-B2 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-03-01 | — | — | US | disclosed |
| EP-1740171-B1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-09 | — | — | EP | disclosed |
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-09-06 | — | — | US | disclosed |
| EP-1740171-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005094816-A1 | INDOL-1-YL-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208004-A1 | Indol-1-yl-acetic acid derivatives | IDO1, IDO2, AANAT | MEN1 2045/4885KMT2A 1575/4885GAA 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.